Interleukin 2
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Interleukin 2
| ||||||||||||||
| ||||||||||||||
| Human Interleukin 2 crystal structure | ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | IL2; IL-2; TCGF; lymphokine | |||||||||||||
| External IDs | OMIM: 147680 MGI: 96548 Homologene: 488 | |||||||||||||
| ||||||||||||||
| RNA expression pattern | ||||||||||||||
|
| ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 3558 | 16183 | ||||||||||||
| Ensembl | ENSG00000109471 | na | ||||||||||||
| Uniprot | P60568 | na | ||||||||||||
| Refseq | NM_000586 (mRNA) NP_000577 (protein) | NM_008366 (mRNA) NP_032392 (protein) | ||||||||||||
| Location | Chr 4: 123.59 - 123.6 Mb | na | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
|
WikiDoc Resources for Interleukin 2 | |
|
Articles | |
|---|---|
|
Most recent articles on Interleukin 2 Most cited articles on Interleukin 2 | |
|
Media | |
|
Powerpoint slides on Interleukin 2 | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Interleukin 2 at Clinical Trials.gov Trial results on Interleukin 2 Clinical Trials on Interleukin 2 at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Interleukin 2 NICE Guidance on Interleukin 2
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Interleukin 2 Discussion groups on Interleukin 2 Patient Handouts on Interleukin 2 Directions to Hospitals Treating Interleukin 2 Risk calculators and risk factors for Interleukin 2
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Interleukin 2 | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signalling molecule, that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (nonself) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity.
Discovery and characterization
The IL-2 molecule was first characterized as a variably glycosylated 15,500 Dalton protein capable of supporting long-term T lymphocyte (T cell) proliferation,[1] and was first purified to homogeneity by immunoaffinity chromatography.[1] The IL-2 molecule was also the first interleukin found to be encoded by a complementary DNA (cDNA),[1] and to mediate its effects via a specific IL-2 receptor.[1] Thus, despite being designated the number 2 interleukin, it was the first interleukin molecule, gene and receptor to be discovered. It was designated number 2 because data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells)[1][1]
IL-2 signaling pathway
Interleukin-2 belongs to a family of cytokines, which includes IL-4, IL-7, IL-9, IL-15 and IL-21. IL-2 signals through a receptor complex consisting of IL-2 specific IL-2 receptor alpha (CD25), IL-2 receptor beta (CD122) and a common gamma chain (γc), which is shared by all members of this family of cytokines. Binding of IL-2 activates the Ras/MAPK, JAK/Stat and PI 3-kinase/Akt signaling modules. More comprehensive details are provided in NetPath.
Physiology and immunology
IL-2 is normally produced by the body during an immune response.[1][1] When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of IL-2, and the expression of IL-2 receptors IL-2R. The IL-2/IL-2R interaction then stimulates the growth, differentiation and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes.[1][1][1] As such, IL-2 is necessary for the development of T cell immunologic memory, one of the unique characteristics of the immune system, which depends upon the expansion of the number and function of antigen-selected T cell clones.
IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs).[1][1][1] After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2[1] Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.
IL-2 has been found to be similar to IL-15 in terms of function.[1] Both cytokines are able to facilitate production of immunoglobulins made by B cells and induce the differentiation and proliferation of natural killer cells.[1][1] The primary differences between IL-2 and IL-15 are found in adaptive immune responses. For example, IL-2 participates in maintenance of T-Regs and reduces self-reactive T cells. On the other hand, IL-15 is necessary for maintaining highly specific T cell responses by supporting survival of CD8 memory T cells. The differences in function in these two cytokines stem from the signal transduction mechanisms and differing receptors.
Uses in medicine
A recombinant form of IL-2 is manufactured by Chiron Corporation with the brand name Proleukin. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The role of IL-2 in HIV therapy remains to be fully determined.
Many of the immunsuppressive drugs used in the treatment of autoimmune diseases such as corticosteroids, and organ transplant rejection (cyclosporine, tacrolimus) work by inhibiting the production of IL-2 by antigen-activated T cells. Others (Rapamycin) block IL-2R signaling, thereby preventing the clonal expansion and function of antigen-selected T cells.
References
External links
Cytokines: interleukins | |
|---|---|
| IL-1 superfamily | IL-1 (IL-1Ra) - IL-18 - IL-33 |
| IL-6 like/gp130 utilizing | IL-6 - IL-11 - IL-27 - IL-30 - IL-31 |
| IL-10 family | IL-10 - IL-19 - IL-20 - IL-22 - IL-24 - IL-26 |
| Interferon type III | IL-28 - IL-29 |
| Common γ-chain family | IL-2/IL-15 - IL-3 - IL-4 - IL-7 - IL-9 - IL-13 - IL-21 |
| IL-12 family | IL-12 - IL-23 - IL-27 - IL-35 |
| Other | IL-5 - IL-8 - IL-14 - IL-16 - IL-17/IL-25 (A) - IL-32 |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
